| abstract |
Pharmaceutical use of lipases involves thermomyses ranuginosa (fumicola ranuginosa) lipase, optionally comprising amino acids 1-269 of SEQ ID NO: 2 in combination with proteases and / or amylases. Examples of medical indications are the treatment of digestive disorders, pancreatic exocrine dysfunction (PEI), pancreatitis, cystic fibrosis, type I diabetes, and / or type II diabetes. Lipases of the invention have, for example, improved digestion performance ex vivo, improved activity at neutral pH ranges, improved activity at low pH, stable to protease-degradation and / or the presence of pepsin and bile salts Stable under The invention also relates to methods for determining the ex vivo digestion performance of lipases and for identifying novel variants of lipases of T. ranugnusus. |